Korean Circ J.  2020 Nov;50(11):961-973. 10.4070/kcj.2020.0308.

Percutaneous Edge-to-Edge Mitral Valve Repair

• Yeo KK
• Wong Ny

• KMID: 2508281
• DOI: http://doi.org/10.4070/kcj.2020.0308

Abstract

Percutaneous edge-to-edge mitral valve repair, using the MitraClip device for severe mitral regurgitation (MR) was first introduced in 2003. Since then, more than 100,000 cases have been performed worldwide and it remains the most established percutaneous therapy available for the treatment of severe MR. Currently, it is indicated for severe, symptomatic functional MR in patients who continue to have significant symptoms despite optimal guideline directed medical therapy, as well as in symptomatic patients with severe degenerative MR who are deemed too high risk for conventional surgical therapy in the opinion of the heart team. In this paper, we discuss the evolution of the MitraClip device, the clinical studies supporting its use as well as the important concept of proportionate and disproportionate MR.

Keyword

Mitral regurgitation; Percutaneous mitral valve repair

Figure

• 

  Figure 1 Evolution of the MitraClip from MitraClip Classic to G4.

Reference

1. Condado JA, Vélez-Gimón M. Catheter-based approach to mitral regurgitation. J Interv Cardiol. 2003; 16:523–534. PMID: 14632950.

2. Condado JA, Acquatella H, Rodriguez L, Whitlow P, Vélez-Gimo M, St Goar FG. Percutaneous edge-to-edge mitral valve repair: 2-year follow-up in the first human case. Catheter Cardiovasc Interv. 2006; 67:323–325. PMID: 16419054.

3. Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011; 364:1395–1406. PMID: 21463154.

4. Lim DS, Reynolds MR, Feldman T, et al. Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after transcatheter mitral valve repair. J Am Coll Cardiol. 2014; 64:182–192. PMID: 24184254.

5. Glower DD, Kar S, Trento A, et al. Percutaneous mitral valve repair for mitral regurgitation in high-risk patients: results of the EVEREST II study. J Am Coll Cardiol. 2014; 64:172–181. PMID: 25011722.

6. Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med. 2018; 379:2297–2306. PMID: 30145927.

7. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018; 379:2307–2318. PMID: 30280640.

8. Feldman T, Kar S, Rinaldi M, et al. Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol. 2009; 54:686–694. PMID: 19679246.

9. Feldman T, Wasserman HS, Herrmann HC, et al. Percutaneous mitral valve repair using the edge-to-edge technique: six-month results of the EVEREST Phase I Clinical Trial. J Am Coll Cardiol. 2005; 46:2134–2140. PMID: 16325053.

10. Rogers JH, Franzen O. Percutaneous edge-to-edge MitraClip therapy in the management of mitral regurgitation. Eur Heart J. 2011; 32:2350–2357. PMID: 21606080.

11. Feldman T, Fernandes E, Levisay JP. Transcatheter mitral valve repair/replacement for primary mitral regurgitation. Ann Cardiothorac Surg. 2018; 7:755–763. PMID: 30598889.

12. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63:2438–2488. PMID: 24603192.

13. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129:e521–643. PMID: 24589853.

14. Stone GW, Weissman NJ, Mack MJ. COAPT Investigators. Transcatheter mitral-valve repair in patients with heart failure. Reply. N Engl J Med. 2019; 380:1980–1981. PMID: 31091394.

15. Obadia JF, Armoiry X, Iung B, et al. The MITRA-FR study: design and rationale of a randomised study of percutaneous mitral valve repair compared with optimal medical management alone for severe secondary mitral regurgitation. EuroIntervention. 2015; 10:1354–1360. PMID: 25798568.

16. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg. 2012; 42:S1–44. PMID: 22922698.

17. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017; 38:2739–2791. PMID: 28886619.

18. Mack MJ, Abraham WT, Lindenfeld J, et al. Cardiovascular outcomes assessment of the MitraClip in patients with heart failure and secondary mitral regurgitation: design and rationale of the COAPT trial. Am Heart J. 2018; 205:1–11. PMID: 30134187.

19. Grayburn PA, Sannino A, Packer M. Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the MITRA-FR and COAPT trials. JACC Cardiovasc Imaging. 2019; 12:353–362. PMID: 30553663.

20. Grayburn PA, Carabello B, Hung J, et al. Defining “severe” secondary mitral regurgitation: emphasizing an integrated approach. J Am Coll Cardiol. 2014; 64:2792–2801. PMID: 25541133.

21. Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003; 16:777–802. PMID: 12835667.

22. Grayburn PA, Weissman NJ, Zamorano JL. Quantitation of mitral regurgitation. Circulation. 2012; 126:2005–2017. PMID: 23071176.

23. Asch FM, Grayburn PA, Siegel RJ, et al. Echocardiographic outcomes after transcatheter leaflet approximation in patients with secondary mitral regurgitation: the COAPT trial. J Am Coll Cardiol. 2019; 74:2969–2979. PMID: 31574303.

24. Maisano F, Franzen O, Baldus S, et al. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. J Am Coll Cardiol. 2013; 62:1052–1061. PMID: 23747789.

25. Nickenig G, Estevez-Loureiro R, Franzen O, et al. Percutaneous mitral valve edge-to-edge repair: in-hospital results and 1-year follow-up of 628 patients of the 2011-2012 Pilot European Sentinel Registry. J Am Coll Cardiol. 2014; 64:875–884. PMID: 25169171.

26. Baldus S, Schillinger W, Franzen O, et al. MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail. 2012; 14:1050–1055. PMID: 22685268.

27. Sorajja P, Vemulapalli S, Feldman T, et al. Outcomes with transcatheter mitral valve repair in the United States: an STS/ACC TVT registry report. J Am Coll Cardiol. 2017; 70:2315–2327. PMID: 29096801.

28. Yeo KK, Yap J, Yamen E, et al. Percutaneous mitral valve repair with the MitraClip: early results from the MitraClip Asia-Pacific Registry (MARS). EuroIntervention. 2014; 10:620–625. PMID: 24425362.

29. Tay E, Muda N, Yap J, et al. The MitraClip Asia-Pacific registry: differences in outcomes between functional and degenerative mitral regurgitation. Catheter Cardiovasc Interv. 2016; 87:E275–81. PMID: 26508564.

30. Hayashida K, Yasuda S, Matsumoto T, et al. AVJ-514 Trial - Baseline characteristics and 30-day outcomes following MitraClip^® treatment in a Japanese cohort. Circ J. 2017; 81:1116–1122. PMID: 28321004.

31. Lee CW, Sung SH, Tsai YL, et al. Initial experience with percutaneous edge-to-edge transcatheter mitral valve repair in a tertiary medical center in Taiwan. J Chin Med Assoc. 2018; 81:305–310. PMID: 29291891.

32. Wong N, Hamid N, Tang HC, Yeo KK. Killing two birds with one stone-MitraClip for flail P2 and systolic anterior motion of mitral valve: a case report. Eur Heart J Case Rep. 2018; 2:yty146. PMID: 31020221.

33. Sorajja P, Pedersen WA, Bae R, et al. First experience with percutaneous mitral valve plication as primary therapy for symptomatic obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2016; 67:2811–2818. PMID: 27311518.

34. Schäfer U, Frerker C, Thielsen T, et al. Targeting systolic anterior motion and left ventricular outflow tract obstruction in hypertrophic obstructed cardiomyopathy with a MitraClip. EuroIntervention. 2015; 11:942–947. PMID: 25169590.

35. Szymanski C, Levine RA, Tribouilloy C, et al. Impact of mitral regurgitation on exercise capacity and clinical outcomes in patients with ischemic left ventricular dysfunction. Am J Cardiol. 2011; 108:1714–1720. PMID: 21943932.

36. Lancellotti P, Gérard PL, Piérard LA. Long-term outcome of patients with heart failure and dynamic functional mitral regurgitation. Eur Heart J. 2005; 26:1528–1532. PMID: 15814566.

37. Lapu-Bula R, Robert A, Van Craeynest D, et al. Contribution of exercise-induced mitral regurgitation to exercise stroke volume and exercise capacity in patients with left ventricular systolic dysfunction. Circulation. 2002; 106:1342–1348. PMID: 12221050.

38. Izumo M, Suzuki K, Moonen M, et al. Changes in mitral regurgitation and left ventricular geometry during exercise affect exercise capacity in patients with systolic heart failure. Eur J Echocardiogr. 2011; 12:54–60. PMID: 20810450.

39. Masumoto A, Kubo S, Ohya M, Maruo T, Kadota K. MitraClip therapy for dynamic mitral regurgitation with repetitive heart failure exacerbation. JACC Cardiovasc Interv. 2019; 12:e215–7. PMID: 31786214.

40. Duino V, Fiocca L, Musumeci G, et al. An intriguing case report of functional mitral regurgitation treated with MitraClip. Medicine (Baltimore). 2015; 94:e608. PMID: 25997036.

41. Taramasso M, Alessandrini H, Latib A, et al. Outcomes after current transcatheter tricuspid valve intervention: mid-term results from the international TriValve registry. JACC Cardiovasc Interv. 2019; 12:155–165. PMID: 30594510.

42. Nickenig G, Weber M, Lurz P, et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet. 2019; 394:2002–2011. PMID: 31708188.

43. Lim DS, Kar S, Spargias K, et al. Transcatheter valve repair for patients with mitral regurgitation: 30-day results of the CLASP study. JACC Cardiovasc Interv. 2019; 12:1369–1378. PMID: 31255562.

44. Abbott Medical Devices. MitraClip REPAIR MR study [Internet]. Bethesda: U.S. National Library of Medicine;2020. cited 2020 Jul 19. Available from: https://clinicaltrials.gov/ct2/show/NCT04198870.